In conclusion, we found that BBSKE synergized the anti-tumor effect of oxaliplatin by inhibiting TrxR1 activity and demonstrated that the combined treatment induced apoptotic cell death through ROS-mediated p38 and JNK signaling pathways. Here, TXNRD1 is linked to neoplasm.